Inicio › Mieloma múltiple › Kansas
Ensayos clínicos de Mieloma múltiple en Kansas
12 estudios sobre Mieloma múltiple buscan participantes en Kansas.
Ciudades en Kansas
Texto oficial del estudio (inglés)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Kansas City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Kansas University Medical Center, Westwood
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Kansas Cancer Center, Kansas City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07258511Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- y 1 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- The University of Kansas Cancer Center - Westwood, Westwood
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Kansas, Westwood
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06980480MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City
- Ascentist Doctors' Hospital, Leawood
- American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Merriam
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Wichita
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Instititute - South, Overland Park
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 19 a 110 · Todos los sexos · Actualizado el 29 jun 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
ReclutandoFase 3
Todas las edades · Todos los sexos · Actualizado el 10 jun 2026 · NCT05561387Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of Kansas Clinical Research Center, Westwood
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT06433947De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.